829 related articles for article (PubMed ID: 18450829)
1. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
2. ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
Böger RH; Schwedhelm E; Maas R; Quispe-Bravo S; Skamira C
Vasc Med; 2005 Jul; 10 Suppl 1():S97-102. PubMed ID: 16444875
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.
Yoshida H; Akasaka H; Saitoh S; Shimamoto K; Miura T;
Hypertens Res; 2014 Mar; 37(3):225-31. PubMed ID: 24108237
[TBL] [Abstract][Full Text] [Related]
4. Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels.
Tomiyama H; Yamada J; Koji Y; Shiina K; Yoshida M; Yamashina A
Am J Hypertens; 2007 Dec; 20(12):1305-11. PubMed ID: 18047921
[TBL] [Abstract][Full Text] [Related]
5. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.
Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S
J Int Med Res; 2005; 33(6):677-86. PubMed ID: 16372586
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study.
Sharma AM; Davidson J; Koval S; Lacourcière Y
Cardiovasc Diabetol; 2007 Oct; 6():28. PubMed ID: 17910747
[TBL] [Abstract][Full Text] [Related]
7. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
Littlejohn T; Mroczek W; Marbury T; VanderMaelen CP; Dubiel RF
Can J Cardiol; 2000 Sep; 16(9):1123-32. PubMed ID: 11021956
[TBL] [Abstract][Full Text] [Related]
8. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
White WB; Murwin D; Chrysant SG; Koval SE; Davidai G; Guthrie R
Blood Press Monit; 2008 Feb; 13(1):21-7. PubMed ID: 18199920
[TBL] [Abstract][Full Text] [Related]
9. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy.
Masuda S; Tamura K; Wakui H; Kanaoka T; Ohsawa M; Maeda A; Dejima T; Yanagi M; Azuma K; Umemura S
Hypertens Res; 2009 Nov; 32(11):950-5. PubMed ID: 19713965
[TBL] [Abstract][Full Text] [Related]
10. Reduction of proteinuria with angiotensin receptor blockers.
Galle J
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S36-43. PubMed ID: 18580865
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction.
Takagi H; Niwa M; Mizuno Y; Goto SN; Umemoto T;
Hypertens Res; 2013 Jul; 36(7):627-33. PubMed ID: 23344134
[TBL] [Abstract][Full Text] [Related]
13. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
Miura Y; Yamamoto N; Tsunekawa S; Taguchi S; Eguchi Y; Ozaki N; Oiso Y
Diabetes Care; 2005 Mar; 28(3):757-8. PubMed ID: 15735228
[No Abstract] [Full Text] [Related]
14. Sustained antihypertensive activity of telmisartan compared with valsartan.
Lacourcière Y; Krzesinski JM; White WB; Davidai G; Schumacher H
Blood Press Monit; 2004 Aug; 9(4):203-10. PubMed ID: 15311147
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
16. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
[TBL] [Abstract][Full Text] [Related]
17. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
White WB; Lacourciere Y; Davidai G
Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
[TBL] [Abstract][Full Text] [Related]
18. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy.
Bakris G; Burgess E; Weir M; Davidai G; Koval S;
Kidney Int; 2008 Aug; 74(3):364-9. PubMed ID: 18496508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
